LIVE

CGEM

Cullinan Therapeutics, Inc.

CGEM

NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $1.1B

$17.63

▲ +2.03%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$5.68 - $19.43

P/E

-4.70

Fwd P/E

-5.82

Beta

0.01

Div Yield

0.00%

Avg Vol

1.1M

Shares Out

60.5M

Mkt Cap

$1.1B

Price action

Price chart

Up 122.7% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Experienced founding team led by renowned scientist Patrick A. Baeuerle
  • Diversified pipeline targeting multiple cancer pathways and mechanisms
  • Focus on immuno-oncology, a high-growth area in cancer therapeutics
▼

Bear Case

1 risk

  • Low volatility (beta 0.0).

Growth

Revenue decline expected

Advancement of clinical-stage candidates through development milestones

Value

Deep value opportunity - significant discount to Healthcare Distribution peers

Momentum

Strong

+19.8% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 6, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of -$0.75 vs -$0.84 consensus (+10.3% surprise).

EPS beat +10.3%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+10.3%

Next: May 6, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

3 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

3

100%

Hold

0%

Sell

0%

Median Price Target

$33.50

▲ +90.0% vs $17.63

Low $30.00
Median $33.50
High $37.00

Latest: BTIG · May 19, 2026

2 analysts covering

View full analyst page →

vs Industry

How CGEM stacks vs Medical - Pharmaceuticals

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.